Bangkok--Jun 2--NIDA
First-Ever Epidemiological Study of ED Finds Widespread Prevalence Amongst Thai Men 3 Million 40-70 Year-Olds Estimated to Suffer from ED; Few Sufferers Actually Seek Treatment, However
The first official epidemiological study of ED in Thailand involving 1,250 men from across the country has revealed that 37.5% of respondents suffer from some degree of erectile dysfunction (ED). The study has led to an estimate that over 3 million 40 to 70 year-old Thai men nationwide may suffer from ED, with 527,120 of them projected to reside in urban areas. Despite this significant figure, two in five sufferers will not discuss the condition with anyone, highlighting the great reluctance of men to tackle ED, which is highly treatable.
The epidemiological study was jointly conducted by the Department of Population and Development, School of Applied Statistics at the National Institute of Development Administration (NIDA), the Erectile Dysfunction Advisory Council & Training Thailand (EDACTT), and Pfizer International during November-December 1998 and involved men from five regions of the country (250 each from Bangkok and the central, northern, northeastern and southern regions) aged 40-70 years old. The average age of study participants was 51 years. In terms of specific breakdown, 19.1% of males classified their ED as mild, 13.7% as moderate, and 4.7% as severe. ED is defined as the consistent inability to attain and/or maintain an erection sufficient for satisfactory sexual activity.
The association between ED and major chronic illnesses such as hypertension, diabetes, heart disease and others, in addition to lifestyle factors such as excessive smoking and drinking, is well documented. In the study the most common major chronic disease was the presence of an ulcer (in 16% of men), followed closely by hypertension (13%) and then diabetes (6%), heart disease (4.2%) and prostatism/prostatitis (1.4%).
Elder males are also known to have a greater likelihood of suffering from multiple chronic illnesses, and this significantly raises the probability of ED. This was made clear in the survey in that, among men who suffer from diabetes, hypertension as well as heart disease, the prevalence of ED is 100%. Related to this, the overall prevalence of ED increased dramatically in the older age groups, moving from approximately 20% of 40-49 year old men to 46% of 50-59 year olds to 73% of 60-70 year olds. These figures were to be expected given that in most cases ED is caused by an underlying medical condition, which appear more frequently in older men.
Other key risk factors for the onset of ED that were examined in the study include medications to treat various illnesses, certain psychological ailments (most notably depression), surgery and trauma to the spinal cord and pelvic regions, as well as lifestyle factors such as heavy smoking and drinking.
One of the most telling results of the study shown by participants was the lack of understanding about ED and its treatment. For instance, about half of those surveyed wrongly suggested that the first course of action in tackling ED is to engage in physical exercise. Even more revealing was the fact that, of the almost 40% who suffer from ED, only 2% (10 men in total) had ever sought treatment. Looking at the total sample size, 41% indicated that they would not consult or
discuss the condition with anyone were they to suffer from ED. A mere 22% said they would consult with a general practitioner.
Commenting on the value of the study, Associate Professor Dr. Apichat Kongkanand, head of EDACTT and a urology specialist at Chulalongkorn University, noted that “the high prevalence of ED among Thai men is not a surprising finding from the epidemiological study. The fact that 4 out of 10 urban dwelling males aged 40 to 70 years suffers from ED serves to highlight that this is a very serious and widespread medical condition. What is worrisome is the minimal understanding that exists about ED and the unwillingness of sufferers to pursue treatment options. It is unfortunate that many men with ED continue to suffer in silence, since the condition has a devastating impact on the quality of life of both ED sufferers and their partners. It is even more unfortunate given that the condition is highly treatable”.
Ms. Beyhan D. Zaim, General Manager, Thailand/Myanmar, Pfizer Pharmaceuticals, remarked that “Pfizer has assumed the global leadership role in educating both the medical community and general public about ED. The results of the Pfizer-sponsored study indicate how vital this role is, as the majority of men continue to be misinformed about ED and sufferers remain reluctant to seek out treatment. Pfizer is directly addressing this area by spearheading efforts to raise awareness and educate relevant parties about ED.
“For instance, Pfizer has been instrumental in educating the medical community about the management of ED through EDACTT. In addition, we will also be embarking on a joint nationwide training program beginning in June with the Thai Medical Association and the FDA to educate doctors regarding the diagnosis and effective treatment of ED.
“These efforts have been complemented by our work in establishing the Information Centre on Men’s Health, a body whose aim is to provide the general public with accurate information and professional advice on key issues affecting men’s health,
including ED. It is our belief that such initiatives will go a long way towards raising the profile of ED in Thailand and, most importantly, to improving the quality of life of ED sufferers and their partners,” Ms. Zaim concluded.
The epidemiological study is also consistent with Ministry of Public Health (MOPH) plans to highlight significant men’s health issues. It was designed to provide long-term benefits to Thai health circles by developing a base of knowledge on ED and using the study as a point of reference in evaluating the success of education efforts regarding ED.
The Erectile Dysfunction Advisory Council and Training Thailand (EDACTT) is comprised of a group of physicians dedicated to developing Thailand-specific programmes to help improve awareness, understanding and management of the medical condition known as erectile dysfunction (ED), in order to enhance the quality of life of patients suffering from ED. EDACTT was established with the same mission and objectives as the Erectile Dysfunction Advisory Council (EDAC), a group of ED medical professionals from Europe, the U.S., Asia and the Middle East who have joined forces to provide accurate information and to educate doctors, ED patients as well as the public about ED diagnosis and treatment.
Pfizer is a research-based healthcare company with global operations. In 1998, the company reported revenues of approximately US$13.5 billion and in 1999 will invest US$2.8 billion in research and development.
For further information, please contact: Pongprach Surojnametakul Derrick Bartel Presko Shandwick (Thailand) Ltd. Tel: 257 0300 Fax: 257 0312 End.